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In June 2003 the British Medical Journal (BMJ) published a paper which claimed that taking a daily pill containing six active ingredients would prevent more than 80% of cardiovascular events. 1 The proposed 'polypill' contains aspirin, a 'statin', three blood pressure lowering agents (a thiazide, a beta blocker and an ACE inhibitor) and folic acid. Few papers have provoked such debate and raised tempers so high. One correspondent wrote:
'I have read some rubbish in medical journals in my time, but none as appallingly bad as this'. On the other hand, the Editor of the BMJ said the paper made that issue of the journal possibly the most important in 50 years.
It is generally accepted that patients with previous cardiovascular disease require treatment with antiplatelet, blood pressure lowering and cholesterol lowering therapies. 2, 3 Where the controversy lies is the concept of a fixed dose, and widespread use of the polypill in primary prevention. (The paper suggested that as death from cardiovascular disease increases with age everyone over 55 years old should take the polypill.)
Mass medication can be justified from a population perspective when the burden of disease is high, but it is difficult to defend at an individual level in those at low risk. show that adding one more class of medication does confer additional reduction in risk, but no-one has carried out a study with as many components as in the proposed polypill. Estimates of benefit range from a relative reduction in risk around 55% to over 80%, according to the composition of a polypill, with those at highest risk achieving the greatest benefit in absolute terms. 1, 3 Would a one-size-fits-all approach be safe and effective? We don't know if a combination approach would magnify the adverse effects of individual components, although there seems no a priori reason to believe it would. It is estimated that the polypill would cause symptoms in 8-15% of people. 1 Some have argued that it would be difficult to tease out which component of the polypill is causing an adverse effect.
However, the same is true in any patient who is taking separate drugs at the same time. The components of the polypill and their adverse effects are well known so it should be possible to attribute the cause of an adverse effect.
Critics claim that for many individuals, risk factors would Intuitively the greatest benefit of a polypill is the simplicity of the regimen, resulting in improved adherence and better clinical outcomes, but surprisingly, few clinical trial data are available. 4 Nevertheless, fixed-dose combinations of four or more medications are being developed for tuberculosis and HIV.
For people with cardiovascular disease, in whom the separate ingredients are recommended, only a small minority receive the full combination. 5 This may result from confusion due to complicated regimens, the sheer inconvenience of managing large numbers of pills, a reluctance to take (or prescribe) multiple medicines, and cost. 
